Literature DB >> 15170660

Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

Jin-Rong Zhou1, Lunyin Yu, Luiz F Zerbini, Towia A Libermann, George L Blackburn.   

Abstract

Lethal phenotypes of human prostate cancer are characterized by progression to androgen-independence and metastasis. For want of a clinically relevant animal model, mechanisms behind this progression remain unclear. Our study used an in vivo model of androgen-sensitive LNCaP human prostate cancer cell xenografts in male SCID mice to study the cellular and molecular biology of tumor progression. Primary tumors were established orthotopically, and the mice were then surgically castrated to withdraw androgens. Five generations of androgen-independent tumors were developed using castrated host mice. Tumor samples were used to determine expressions of cellular and molecular markers. Androgen-independent tumors had increased proliferation and decreased apoptosis compared to androgen-sensitive tumors, outcomes associated with elevated expression of p53, p21/waf1, bcl-2, bax and the bcl-2/bax ratio. Blood vessel growth in androgen-independent tumor was associated with increased expression of vascular endothelial growth factor. Overexpression of androgen receptor mRNA and reduced expression of androgen receptor protein in androgen-independent tumors suggest that the androgen receptor signaling pathway may play an important role in the progression of human prostate cancer to androgen-independence. The in vivo orthotopic LNCaP tumor model described in our study mimics the clinical course of human prostate cancer progression. As such, it can be used as a model for defining the molecular mechanisms of prostate cancer progression to androgen-independence and for evaluating the effect of preventive or therapeutic regimens for androgen-independent human prostate cancer. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170660      PMCID: PMC2683255          DOI: 10.1002/ijc.20206

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

1.  Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

Authors:  M J Linja; K J Savinainen; O R Saramäki; T L Tammela; R L Vessella; T Visakorpi
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

Review 2.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

3.  Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.

Authors:  D B Agus; C Cordon-Cardo; W Fox; M Drobnjak; A Koff; D W Golde; H I Scher
Journal:  J Natl Cancer Inst       Date:  1999-11-03       Impact factor: 13.506

4.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

5.  Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.

Authors:  H Kinoshita; Y Shi; C Sandefur; L F Meisner; C Chang; A Choon; C R Reznikoff; G S Bova; A Friedl; D F Jarrard
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Authors:  G N Thalmann; R A Sikes; T T Wu; A Degeorges; S M Chang; M Ozen; S Pathak; L W Chung
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

7.  Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.

Authors:  R Mazzucchelli; R Montironi; A Santinelli; G Lucarini; A Pugnaloni; G Biagini
Journal:  Prostate       Date:  2000-09-15       Impact factor: 4.104

8.  Low apoptotic activity in primary prostate carcinomas without response to hormonal therapy.

Authors:  C Palmberg; I Rantala; T L Tammela; H Helin; P A Koivisto
Journal:  Oncol Rep       Date:  2000 Sep-Oct       Impact factor: 3.906

9.  Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts.

Authors:  R J Stewart; D Panigrahy; E Flynn; J Folkman
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

10.  Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components.

Authors:  Jin-Rong Zhou; Lunyin Yu; Ying Zhong; Rena L Nassr; Adrian A Franke; Sandra M Gaston; George L Blackburn
Journal:  Prostate       Date:  2002-10-01       Impact factor: 4.104

View more
  12 in total

Review 1.  Androgen regulation of prostate cancer: where are we now?

Authors:  G Corona; E Baldi; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-02-04       Impact factor: 4.256

2.  Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis.

Authors:  Ajita V Singh; Adrian A Franke; George L Blackburn; Jin-Rong Zhou
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

3.  Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.

Authors:  Yi Gong; Yanli Li; Yin Lu; Linglin Li; Hamid Abdolmaleky; George L Blackburn; Jin-Rong Zhou
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

4.  Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method.

Authors:  Nicholas G Zaorsky; Tianyu Li; Karthik Devarajan; Eric M Horwitz; Mark K Buyyounouski
Journal:  Cancer       Date:  2012-04-27       Impact factor: 6.860

5.  Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Chiech Huo; Liang-Cheng Su; Shutsung Liao
Journal:  Cancer Sci       Date:  2011-08-18       Impact factor: 6.716

6.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Li Yan; Linda A Snyder; Kenneth J Pienta
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

Review 7.  Systematic review of hypofractionated radiation therapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den
Journal:  Cancer Treat Rev       Date:  2013-03-01       Impact factor: 12.111

8.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

9.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.

Authors:  Thirupandiyur S Udayakumar; Paul Hachem; Mansoor M Ahmed; Sudhir Agrawal; Alan Pollack
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

10.  Development of the VCaP androgen-independent model of prostate cancer.

Authors:  Robert D Loberg; Lauren N St John; LaShon L Day; Chris K Neeley; Kenneth J Pienta
Journal:  Urol Oncol       Date:  2006 Mar-Apr       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.